April 6, 2026

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Tom Kerr
312-265-9417
tkerr@zacks.com

scr.zacks.com

101 N. Wacker Drive, Chicago, IL 60606

Vireo Growth Inc. (OTCQX: VREOF)

VREOF: Vireo announces 4th quarter and full year 2025 financial and operating results which showed strong organic sales momentum.

Utilizing a Discounted Cash Flow process containing conservative estimates combined with other valuation methodologies, we believe VREOF could be worth **$1.50** per share.

Current Price (4/2/26)	$0.40
Valuation	**$1.50**

OUTLOOK

Vireo Growth (VREOF) is a vertically integrated cannabis Multiple State Operator (MSO) involved in the cultivation, production, and distribution of a diversified suite of medical and recreational products to proprietary retail outlets and third-party dispensaries in wholesale markets. Following the early 2025 closed acquisitions and the announced acquisitions at the end of 2025, the company's operating footprint covers CA, CO, FL, MD, MN, MO, NM, NV, NY, and UT. The company also owns eight cultivation facilities and 38 dispensaries. The company appears to be positioned for strong growth going forward.

SUMMARY DATA

52-Week High	**$0.80**
52-Week Low	**$0.31**
One-Year Return (%)	**-13.9**
Beta	**N/A**
Average Daily Volume (sh)	**171,272**
Shares Outstanding (mil)	**1,177**
Market Capitalization ($mil)	**$430**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**11**
Insider Ownership (%)	**27**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2026 Estimate	**13.1**
P/E using 2027 Estimate	**N/A**

Risk Level	**Above Average**
Type of Stock	**Small Growth**
Industry	**Medical Products**

ZACKS ESTIMATES

Revenues
(in thousands of $)

	Q1 (Mar)	**Q2** (Jun)	**Q3** (Sep)	**Q4** (Dec)	**Year** (Dec)
2023	19,088 A	20,197 A	24,675 A	24,173 A	88,133 A
2024	24,087 A	25,108 A	25,165 A	25,023 A	99,384 A
2025	24,541 A	48,063 A	91,655 A	104,500 A	268,769 A
2026					573,537 E

Earnings/Share

	Q1 (Mar)	**Q2** (Jun)	**Q3** (Sep)	**Q4** (Dec)	**Year** (Dec)
2023	($0.07) A	($0.06) A	($0.04) A	($0.03) A	($0.19) A
2024	($0.05) A	($0.00) A	($0.02) A	($0.07) A	($0.16) A
2025	($0.02) A	($0.03) A	($0.04) A	($0.02) A	($0.09) A
2026	$0.00) E	$0.01 E	$0.01 E	$0.01 E	$0.03 E

Quarterly revenues/EPS may not equal annual revenues/EPS due to rounding.

WHAT'S NEW

<u>4th Quarter 2025 Financial Results</u>

On March 17, 2026, Vireo announced 4th quarter 2025 financial results which showed impressive revenue growth and margin improvement.

Reported revenue growth increased 317.7% to $104.5 million from $25 million in the prior year period largely due to acquisitions in early 2025. However, on a pro forma basis, 4th quarter same store sales increased 22% year-over-year and wholesale revenue increased 55% year-over-year. Excluding Minnesota, same-store sales increased 11.3% year-over-year. Sequential revenue growth was also strong increasing 14.0% from Q3 2025 to Q4 2025.

Reported adjusted EBITDA increased 347% and pro-forma adjusted EBITDA increased 30% for the 4th quarter. EBITDA margin improved to 28.2% compared to 27.4% for the prior year period. This was primarily driven by continued optimization of previous acquisitions.

At the end of 2025, the company had $122.5 million of cash and an additional $1.0 million of marketable securities. Total current assets excluding tax receivables, assets held for sale and the Schwazze notes receivable were $204.1 million, compared to current liabilities excluding uncertain tax liabilities of $71.6 million creating a strong current ratio of 2.85x.

	Three Months Ended December 31, 2025	Three Months Ended December 31, 2024 (pro forma)[1]	$ Change	% Change
Retail:				
MN	$ 18,863,457	$ 11,221,254	$ 7,642,203	68 %
NY	923,579	1,307,983	(384,404)	(29)%
MD	6,925,872	6,846,072	79,800	1 %
UT	12,008,798	10,676,764	1,332,034	12 %
NV	27,930,111	23,785,577	4,144,534	17 %
MO	21,323,106	18,328,070	2,995,036	16 %
Total Retail	**$ 87,974,923**	**$ 72,165,720**	**$ 15,809,203**	**22 %**
Wholesale:				
MN	$ 98,993	133,606	(34,613)	(26)%
NY	6,838,607	1,499,647	5,338,960	356 %
MD	3,496,948	4,014,754	(517,806)	(13)%
UT	2,021,769	1,644,832	376,937	23 %
NV	53,845	350,631	(296,786)	(85)%
MO	4,025,377	3,045,323	980,054	32 %
Total Wholesale	**$ 16,535,539**	**$ 10,688,793**	**$ 5,846,746**	**55 %**
Total Revenue	**$ 104,510,462**	**$ 82,854,513**	**$ 21,655,949**	**26 %**

[1]Pro forma results give effect to the Mergers as if they were completed on October 1, 2024. Pro forma information has been presented for informational purposes only and is not necessarily indicative of the Company's past results of operations, nor is it indicative of the future operating results of the Company and should not be considered a substitute for the financial information presented in accordance with GAAP.

Source: investors.vireogrowth.com

FOOTPRINT EXPANSION

vireo

Source: vireogrowth.com

Following the transformational acquisitions of Wholesome, Proper Brands, and Deep Roots Harvest in the first half of 2025, management has remained aggressive on the M&A front. Management remains focused on building a diversified network of local operators across financially attractive and complementary markets that offer a high ROI over time.

On a pro forma basis, Vireo Growth will operate 166 dispensaries across 10 states (CA, CO, FL, MD, MN, MO, NM, NV, NY, and UT), with approximately 800,000 square feet of cultivation and production facilities, as market shares continue to roll up to scale-enabled Multi-State Operators (MSOs). While independent management teams retain control of day-to-day operations, affiliated companies can leverage shared corporate services to facilitate operating efficiencies and enhance growth. From a financing standpoint, Vireo's strong balance sheet remains a key competitive advantage relative to many other U.S.-based cannabis operators that typically struggle to source capital to fund growth. Vireo maintains strong liquidity to continue to capitalize on accelerating consolidation trends across the industry, with $122.5 million of cash on the balance sheet as of 12/31/25. Most of the debt on the balance sheet does not come due until 2028.

Eaze Inc.

In December 2025, Vireo announced the company entered into a merger agreement with Eaze Inc., an MSO with 65 retail dispensaries across California (12), Colorado (14), and Florida (39). The acquisition further diversifies the company's geographic footprint by adding scale-enabled operations in two of the largest markets is the U.S., California and Florida. Eaze manages California's largest legal cannabis marketplace providing access through on-demand delivery, with 12+ million cannabis deliveries since inception, while maintaining outsized cultivation capacity in Florida. Management seems open to further acquisitions in Florida, with Eaze acting as the company's initial foothold.

The base consideration is $47 million (adjusted for cash, indebtedness, transaction expenses, working capital, and tax items) and financed by the issuance of 83.9 million subordinate voting shares of VREOF (subject to staggered lock-up periods commencing in March 2027 through March 2028) at $0.56 per share. In addition, former Eaze stockholders may be entitled to earnout payments (in the form of incremental subordinate voting shares of VREOF priced at the higher of $1.05 or the 20-day Volume-Weighted Average Price as of 12/31/26) based on 3.84x Eaze's Adjusted EBITDA for 2026 less the base consideration. The transaction closed on April 1, 2026.

PharmaCann

In mid-December 2025, Vireo announced the company entered into an Asset Purchase agreement with PharmaCann involving the sale of 17 retail cannabis dispensaries in Colorado in exchange for a share consideration of $49 million (adjusted for changes in inventories/trade payables). This was financed by the issuance of ~116.7 million subordinate voting shares of VREOF (based on the stock's current price), as well as the assumption of certain liabilities. In addition, Vireo and PharmaCann entered into a Management Services Agreement in which the company will provide certain management services related to the dispensaries until the closing of the transaction (expected in the first half of 2026). This transaction further expands Vireo's retail presence in Colorado to 55 dispensaries on a pro forma basis.

Schwazze

In October 2025, Vireo Growth announced the acquisition of ~$91 million of 13% senior secured convertible notes issued by Medicine Man Technologies / Schwazze (OTCPK: SHWZ) in exchange for 114.8 million subordinate voting shares of VREOF at $0.54 (~$62 million in aggregate). The two companies entered into a Restructuring Support Agreement that contemplates the sale of select Schwazze assets to a NewCo (majority-owned by Vireo), as well as the liquidation/wind down of Schwazze's remaining operations. Schwazze is currently in default on the company's payment obligations related to the convertible notes. Vireo has secured financing commitments for up to $62 million for refinancing and working capital needs. Subsequently, Vireo acquired an additional $2.6 million of the convertible notes in mid-December 2025 bringing the company's ownership stake to 89% of SHWZ's total outstanding senior secured convertible notes. In March 2026, the company announced it closed its acquisition of Schwazze assets.

Schwazze is a vertically integrated MSO based in Denver with 46 retail dispensaries and two manufacturing facilities across Colorado and New Mexico. Focusing on Colorado, Schwazze remains the largest cannabis operator in the state, though market shares remain fragmented. That said, the state seems primed for ongoing consolidation following a more challenging industry backdrop, with VREOF seemingly well positioned to continue to roll up market share, thereby further enhancing the company's scale and buying power in Colorado.

Hawthorne

In January 2026, the company announced a nonbinding Memorandum of Understanding (MOU) with The Scotts Miracle-Gro Company (SMG) to acquire The Hawthorne Gardening Company LLC, a provider of indoor/hydroponic gardening products. The proposed acquisition involves equity participation in Vireo through the issuance of subordinate voting shares and is expected to close in the 1st quarter of 2026.

Company management commented that this transaction represents the first step in building a national procurement and supply chain platform with meaningful scale and recurring revenue. Vireo plans on using this platform to purchase ancillary products used across the overall business in a cost-effective manner. Hawthorne has moved past their Capex inventory-focused sales model and into a more Opex-focused model of monthly recurring sales, which management believes is the first step to succeeding in this ancillary market.

The proposed terms as updated in March 2026 would be that Vireo would acquire Hawthorne with at least US$35 million of cash, approximately US$50 million of net working capital, and would be provided with approximately US$20 million of inventory comprised mostly of soil to be supplied to Vireo over two years. The consideration to Hawthorne would be the issuance of 206 million subordinate voting shares of Vireo and a warrant to purchase 80 million shares at an exercise price of US$0.85 per share.

ACCRETION

During the 4th quarter of 2025, the company completed the key integration work related to the transactions that closed in 2025, including integrating HR, ERP platforms, rationalizing insurance providers and policies, and centralizing procurement across the entire enterprise. According to management, these actions have already generated meaningful corporate overhead and ongoing operating synergies, which are expected to become even more evident in full year 2026 results.

Based on those actions, there could be a major step up in earnings power following the closing of the Schwazze, PharmaCann, and Eaze transactions. Beyond the rise in revenue related to VREOF's most recent transactions (partially offset by incremental corporate overhead, interest, and minority interest expenses), key organic growth drivers include the launch of adult-use sales in Minnesota, and a step up in New York revenues reflecting the commencement of adult-use sales from the company's indoor facility.

From a margin perspective, the integrations of Proper, Deep Roots, and Wholesome have largely been completed which included consolidating accounting, finance, human resources, insurance, and procurement operations, with related synergies likely to be fully realized in 2026. Furthermore, a favorable sales mix shift in favor of higher-margin recreational-use products in the retail channel, as well as management's continued focus on driving operational efficiencies and economies of scale more broadly likely result in a step up in profitability.

We believe Adjusted EBITDA (excludes non-cash inventory adjustments and stock-based compensation expenses, as well as non-recurring items) points to additional accretion related to the pending Schwazze, PharmaCann, and Eaze acquisitions.

RESCHEDULING UPDATE

The Trump administration issued an executive order in December 2025 instructing the attorney general to expedite the process of rescheduling marijuana to Schedule III of the Controlled Substances Act. Looking ahead, assuming the Drug Enforcement Administration (DEA) publishes a final rule in the Federal Register following Health and Human Services (HHS) scientific and medical evaluations, a public comment period, and potential hearings, we would expect opponent groups to immediately file a "petition for review" and request a "motion to stay" to suspend the effective date. If a judge denies the motion to stay, rescheduling takes effect. That said, if the stay is granted, the ruling remains suspended pending the outcome of related litigation, which could persist for many years.

As a review, the rescheduling of marijuana from Schedule I to Schedule III potentially paves the way for several key benefits for cannabis-related businesses:

1) IRS Code Section 280E would no longer apply, thereby allowing for the deduction of business expenses on federal tax returns. Beyond immediate cash flow benefits on a go-forward basis, cannabis companies likely settle outstanding liabilities with the government (VREOF carried approximately $120 million of uncertain tax liabilities on the balance sheet as of 12/31/25).

2) Marijuana rescheduling likely improves access to banking/financial services for cannabis companies, thereby lowering costs of capital, all else equal.

3) Less onerous tax burdens potentially promote stepped-up spending on marketing and/or research and development, thus enhancing sustainable growth across cycles. More broadly,

lower regulatory/financial barriers likely spur growth across the industry, with scale-enabled MSOs seemingly well positioned to gain market share, we believe.

As uncertainty around rescheduling probabilities, implications, and timelines fade, we look for cannabis stocks to benefit from meaningful upward revaluations. Further catalysts include potential uplistings to senior exchanges (NYSE, Nasdaq) here in the U.S., which could enhance liquidity and institutional shareholder ownership for public-traded cannabis companies.

KEY INVESTMENT POINTS

Source: vireogrowth.com

Vireo Growth is a vertically integrated cannabis Multiple State Operator (MSO) involved in the cultivation, production, and distribution of a diversified suite of medical and recreational products across proprietary retail outlets and third-party dispensaries in wholesale markets.

Our investment thesis revolves around:

- Transformational Acquisitions: Following the recently closed acquisitions of Wholesome (Utah), Proper Brands (Missouri), and Deep Roots Harvest (Nevada), the company's diversified operating footprint spans six states (including legacy markets in Maryland, Minnesota, and New York), eight cultivation facilities, and 38 dispensaries. Management remains focused on building a diversified network of local operators across financially attractive and complementary markets. While independent management teams retain control of day-to-day operations, affiliated companies can leverage shared corporate services to facilitate operating efficiencies and enhance growth. In late 2025, the company announced additional accretive acquisitions which will expand its market footprint to 10 states.

- Multi-Layered Growth Story: Despite ongoing regulatory uncertainty, we see a number of broader industry and company-specific catalysts that position VREOF for accelerating growth going forward. First, U.S. cannabis industry revenues reached ~$32 billion last year in 2024, with ongoing growth projected driven by further legalization at the state level, rising consumer demand, and a step up in the number of users reflecting growing adoption of cannabis to treat a wider array of medical conditions, as well as building acceptance/support for legalization efforts. For Vireo, we suspect much of the standalone business's growth will come from Minnesota and New York, where management remains focused on building out cultivation/production capacity to meet building adult-use demand. Furthermore, following the previously announced transformational acquisitions, we believe Vireo has reached critical mass, with market shares continuing to roll up to scale-enabled MSOs.

- Profitability Inflection: Our model calls for EPS to hit $0.03 in 2026 reflecting full-year accretion from recent acquisitions, with further growth expected in 2027 and beyond as the business continues to scale. Focusing on the top line, we look for strong growth in 2026 and beyond following the closings of the Wholesome, Proper, and Deep Roots acquisitions, as well as the commencement of adult-use sales in Minnesota. Furthermore, we forecast a step up in New York revenue reflecting the recent initiation of adult-use sales from the company's indoor facility. Turning to margins, key expansion drivers likely include meaningful transaction-related accretion, as senior officials rationalize redundant corporate services across accounting/finance, legal, human resources, and other departments, a constructive mix shift in favor of more profitable sales of recreational-use products in the retail channel, and an ongoing focus on expense management.

- Balance Sheet Strength: Vireo's strong balance sheet remains a key competitive advantage relative to most other U.S.-based cannabis operators that typically struggle to source capital to fund growth due to regulatory restrictions, with highly dilutive financings often the only course of action. Put another way, Vireo maintains ample liquidity to weather the storm and capitalize on accelerating consolidation trends across the industry should the regulatory backdrop remain challenging. Importantly, Vireo's debt profile remains generally favorable, with long-dated maturities (mostly 2028).

- Attractive Valuation: We believe VREOF stock trades at a significant discount from its peers and our DCF calculation. There appear to be multiple catalysts in 2026 & 2027 that may close that valuation gap.

VALUATION & ESTIMATES

We are maintaining our price target of **$1.50** as we wait on further growth metrics results and the closing of the most recent acquisitions. This valuation level still represents meaningful upside potential from current levels. Our view is that once uncertainty related to the closing/integration of pending acquisitions fades (old and recent), VREOF's improving fundamental story will increasingly resonate with investors, thereby driving a material upward revaluation for the stock. Vireo remains uniquely positioned to continue to roll up accretive assets, with further acquisitions likely representing incremental catalysts for the stock

In addition, a more favorable regulatory backdrop (particularly as it relates to federal rescheduling or incremental state legalizations) and/or further acquisitions of strategically complementary assets at attractive valuations likely represent powerful catalysts for VREOF. Finally, insiders (including directors and executive officers along with investment vehicles managed by related party Chicago Atlantic) own approximately 40% of VREOF's total capital stock, reinforcing strong management alignment.

Our DCF model suggests a wide disconnect between VREOF's fundamentals and the stock's current price. Key inputs include: 1) EBIT margin forecasts through 2026; 2) slowing EBIT growth through the end of the forecast period; 3) a 12.5% discount rate; 4) a perpetual growth rate of 5% despite sustainably higher growth rates for the foreseeable future; and 5) an exit EV/EBITDA multiple of 6.0x**.**

Based on expected deal closings from recent acquisition announcements, we update our 2026 estimates to $573.5 million and our 2026 EPS estimate is now $0.03.

Source: vireogrowth.com

INVESTMENT RISKS

- Regulatory uncertainty: The cannabis regulatory landscape remains challenging characterized by ongoing bans at the federal level, a patchwork of differing rules and regulations across states, and continual competition from the black market. The federal Controlled Substances Act (CSA) criminalizes the manufacture, sale, and distribution of Schedule I drugs including marijuana, while the Bank Secrecy Act (BSA) requires depository and other financial institutions to ensure clients refrain from engaging in unlawful behavior, including the sales of marijuana, as well as maintain Anti-Money Laundering (AML) programs. Because if this, cannabis operators often struggle to access traditional financial services and funding from banking institutions, thereby driving elevated operating expenses and higher costs of capital, all else equal.

- M&A integration and financing: All M&A transactions carry meaningful execution and operational risks. And while VREOF manages a decentralized platform leveraging independent operators' local expertise, business dislocation risk rises as accounting/finance, human resources, legal, and other back-office functions are consolidated. Looking ahead, management remains patient, but aggressive as it relates to potentially capitalizing on incremental M&A opportunities. That said, shareholders likely risk dilution, assuming prospective deals are at least partially financed with equity.

- Rising competition: The cannabis industry remains highly fragmented, with ~15,000 dispensaries across the U.S. managed by scale-enabled MSOs and smaller local operators (not to mention the unregulated black market). As such, competition remains fierce, with market shares rolling up to companies that can increasingly leverage superior cultivation and manufacturing capabilities, diversified/innovative product sets, broader retail distribution, more cost-effective marketing initiatives, wider access to financing, and improving operational efficiencies. One of the byproducts of rising competition has been ongoing pricing pressure. Lower prices combined with rising labor/materials costs linked to inflation continues to pressure industry margins, all else equal, with mounting cannabis exports and new market entrants potentially exacerbating the softening pricing trend.

- Uncertain tax liabilities: Section Rule 280E of the Internal Revenue Code prohibits companies that traffic in Schedule I or Schedule II controlled substances from deducting ordinary business expenses (with the exception of certain cultivation and manufacturing costs) resulting in outsized tax burdens and less capital to fund growth. Vireo filed amended tax returns for 2020, 2021, and 2022 that allow for standard business expense deductions. While it remains to be seen if the IRS challenges the deductions, one potential outcome is the company is forced to pay back taxes (plus interest).



Source: vireogrowth.com

PROJECTED INCOME STATEMENT

Vireo Growth Inc. ($ thousands)	1Q25 Mar-25	2Q25 Jun-25	3Q25 Sep-25	4Q25E Dec-25	1Q26 Mar-26	2Q26 Jun-26	3Q26 Sep-26	4Q26E Dec-26	Annual 2023 Dec-23	2024 Dec-24	2025E Dec-25	2026E Dec-26
Revenue	**24,541**	**48,063**	**91,655**	**104,510**	**109,830**	**144,010**	**153,305**	**166,392**	**88,133**	**99,384**	**268,769**	**573,537**
Cost of Sales:												
Product costs	11,695	23,719	40,878	45,717	51,620	67,685	72,053	78,204	42,740	48,319	122,009	269,562
Non-cash product costs		4,152	12,398	1,256							17,805	0
Inventory valuation adjustments	433	(226)	996	656					1,289	294	1,859	0
Gross profit	12,412	20,418	37,383	56,882	58,210	76,325	81,252	88,188	44,104	50,771	127,095	303,975
	50.6%	**42.5%**	**40.8%**	**54.4%**	**53.0%**	**53.0%**	**53.0%**	**53.0%**				
Operating Expenses:												
Selling, general and administrative	7,474	12,455	29,681	31,577	32,620	42,627	45,225	48,919	28,218	28,063	81,187	169,391
Transaction related	1,245	4,729	804	4,430	3,000	2,000	1,000	1,000	0	4,504	11,208	7,000
Stock-based compensation	1,461	4,151	4,007	9,046	1,000	1,000	1,000	1,000	4,158	3,628	18,664	4,000
Depreciation	77	388	553	10,320	10,320	10,320	10,320	10,320	470	293	11,338	41,281
Amortization	180	714	1,530	3,323	1,500	1,500	1,500	1,500	679	720	5,748	6,000
Total Operating Expenses	**10,437**	**22,437**	**36,574**	**58,697**	**48,440**	**57,447**	**59,045**	**62,740**	**33,524**	**37,208**	**128,144**	**227,672**
Operating Income/(Loss)	**1,976**	**(2,019)**	**809**	**(1,814)**	**9,770**	**18,878**	**22,206**	**25,448**	**10,580**	**13,563**	**(1,049)**	**76,303**
Other Income/(Expense):												
Interest expenses, net	(7,600)	(7,648)	(6,906)	(8,101)	(8,101)	(8,101)	(8,101)	(8,101)	(31,261)	(31,189)	(30,254)	(32,403)
Impairment of long-lived assets	0	0	0	(2,600)					(412)	0	(2,600)	0
Gain/(loss) on disposal of assets	0	(6)	(7,838)	(24)					(4,478)	(218)	(7,867)	0
Other income/(expenses)	790	(408)	983	494					7,746	949	1,859	0
Other income/(expenses), net	(6,809)	(8,061)	(13,761)	(10,231)	(8,101)	(8,101)	(8,101)	(8,101)	(28,404)	(30,458)	(38,863)	(32,403)
Pre-Tax Income/(Loss)	**(4,834)**	**(10,080)**	**(12,952)**	**(12,046)**	**1,669**	**10,777**	**14,106**	**17,347**	**(17,824)**	**(16,895)**	**(39,911)**	**43,900**
Current income tax expenses	(1,675)	(4,854)	(13,347)	(21,733)	(584)	(3,233)	(4,232)	(6,072)	(6,036)	(11,113)	(41,609)	(14,121)
Deferred income tax recoveries	0	0	0	13,406					(1,687)	0	13,406	0
Net Income/(Loss)	**(6,509)**	**(14,934)**	**(26,299)**	**(20,373)**	**1,085**	**7,544**	**9,874**	**11,276**	**(25,547)**	**(28,008)**	**(68,114)**	**29,779**
Earnings/(loss) per share	**($0.02)**	**($0.03)**	**($0.04)**	**($0.02)**	**$0.00**	**$0.01**	**$0.01**	**$0.01**	**($0.19)**	**($0.16)**	**($0.09)**	**$0.03**

Source: Company reports and Zacks SCR estimates and calculations.

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research (“ZIR”), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Michael Kim, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer’s business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.